284 related articles for article (PubMed ID: 18642075)
1. Promoter methylation patterns of ATM, ATR, BRCA1, BRCA2 and p53 as putative cancer risk modifiers in Jewish BRCA1/BRCA2 mutation carriers.
Kontorovich T; Cohen Y; Nir U; Friedman E
Breast Cancer Res Treat; 2009 Jul; 116(1):195-200. PubMed ID: 18642075
[TBL] [Abstract][Full Text] [Related]
2. Single-nucleotide polymorphisms in the p53 pathway genes modify cancer risk in BRCA1 and BRCA2 carriers of Jewish-Ashkenazi descent.
Yarden RI; Friedman E; Metsuyanim S; Olender T; Ben-Asher E; Papa MZ
Mol Carcinog; 2010 Jun; 49(6):545-55. PubMed ID: 20306497
[TBL] [Abstract][Full Text] [Related]
3. Cancer risk in Jewish BRCA1 and BRCA2 mutation carriers: effects of oral contraceptive use and parental origin of mutation.
Bernholtz S; Laitman Y; Kaufman B; Paluch Shimon S; Friedman E
Breast Cancer Res Treat; 2011 Sep; 129(2):557-63. PubMed ID: 21499684
[TBL] [Abstract][Full Text] [Related]
4. Histopathological features of breast cancer in carriers of ATM gene variants.
Balleine RL; Murali R; Bilous AM; Farshid G; Waring P; Provan P; Byth K; Thorne H; ; Kirk JA
Histopathology; 2006 Nov; 49(5):523-32. PubMed ID: 17064299
[TBL] [Abstract][Full Text] [Related]
5. Frequency of the ATM IVS10-6T-->G variant in Australian multiple-case breast cancer families.
Lindeman GJ; Hiew M; Visvader JE; Leary J; Field M; Gaff CL; Gardner RJ; Trainor K; Cheetham G; Suthers G; Kirk J
Breast Cancer Res; 2004; 6(4):R401-7. PubMed ID: 15217508
[TBL] [Abstract][Full Text] [Related]
6. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
[TBL] [Abstract][Full Text] [Related]
7. Promoter hypermethylation of the PALB2 susceptibility gene in inherited and sporadic breast and ovarian cancer.
Potapova A; Hoffman AM; Godwin AK; Al-Saleem T; Cairns P
Cancer Res; 2008 Feb; 68(4):998-1002. PubMed ID: 18281473
[TBL] [Abstract][Full Text] [Related]
8. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
[TBL] [Abstract][Full Text] [Related]
9. ATM germline mutations in Spanish early-onset breast cancer patients negative for BRCA1/BRCA2 mutations.
Brunet J; Gutiérrez-Enríquez S; Torres A; Bérez V; Sanjosé S; Galceran J; Izquierdo A; Menéndez JA; Gumà J; Borràs J
Clin Genet; 2008 May; 73(5):465-73. PubMed ID: 18384426
[TBL] [Abstract][Full Text] [Related]
10. Germline mutations in BRCA1 and BRCA2 genes in ethnically diverse high risk families in Israel.
Laitman Y; Borsthein RT; Stoppa-Lyonnet D; Dagan E; Castera L; Goislard M; Gershoni-Baruch R; Goldberg H; Kaufman B; Ben-Baruch N; Zidan J; Maray T; Soussan-Gutman L; Friedman E
Breast Cancer Res Treat; 2011 Jun; 127(2):489-95. PubMed ID: 20960228
[TBL] [Abstract][Full Text] [Related]
11. Germline mutations in the BRCA1 and BRCA2 genes in Turkish breast/ovarian cancer patients.
Manguoglu AE; Lüleci G; Ozçelik T; Colak T; Schayek H; Akaydin M; Friedman E
Hum Mutat; 2003 Apr; 21(4):444-5. PubMed ID: 12655560
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive genetic characterization of hereditary breast/ovarian cancer families from Slovakia.
Konecny M; Milly M; Zavodna K; Weismanova E; Gregorova J; Mlkva I; Ilencikova D; Kausitz J; Bartosova Z
Breast Cancer Res Treat; 2011 Feb; 126(1):119-30. PubMed ID: 21203900
[TBL] [Abstract][Full Text] [Related]
13. Contribution of mutations in ATM to breast cancer development in the Czech population.
Soukupova J; Dundr P; Kleibl Z; Pohlreich P
Oncol Rep; 2008 Jun; 19(6):1505-10. PubMed ID: 18497957
[TBL] [Abstract][Full Text] [Related]
14. BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study.
Baldwin RL; Nemeth E; Tran H; Shvartsman H; Cass I; Narod S; Karlan BY
Cancer Res; 2000 Oct; 60(19):5329-33. PubMed ID: 11034065
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic factors controlling the BRCA1 and BRCA2 genes in sporadic ovarian cancer.
Chan KY; Ozçelik H; Cheung AN; Ngan HY; Khoo US
Cancer Res; 2002 Jul; 62(14):4151-6. PubMed ID: 12124354
[TBL] [Abstract][Full Text] [Related]
16. Coinheritance of BRCA1 and BRCA2 mutations with Fanconi anemia and Bloom syndrome mutations in Ashkenazi Jewish population: possible role in risk modification for cancer development.
Koren-Michowitz M; Friedman E; Gershoni-Baruch R; Brok-Simoni F; Patael Y; Rechavi G; Amariglio N
Am J Hematol; 2005 Mar; 78(3):203-6. PubMed ID: 15726604
[TBL] [Abstract][Full Text] [Related]
17. Promoter hypermethylation patterns in fallopian tube epithelium of BRCA1 and BRCA2 germ line mutation carriers.
Bijron JG; van der Groep P; van Dorst EB; Seeber LM; Sie-Go DM; Verheijen RH; van Diest PJ
Endocr Relat Cancer; 2012 Feb; 19(1):69-81. PubMed ID: 22143498
[TBL] [Abstract][Full Text] [Related]
18. Peripheral blood DNA methylation detected in the BRCA1 or BRCA2 promoter for sporadic ovarian cancer patients and controls.
Bosviel R; Michard E; Lavediaux G; Kwiatkowski F; Bignon YJ; Bernard-Gallon DJ
Clin Chim Acta; 2011 Jul; 412(15-16):1472-5. PubMed ID: 21557934
[TBL] [Abstract][Full Text] [Related]
19. A high occurrence of BRCA1 and BRCA2 mutations among Czech hereditary breast and breast-ovarian cancer families.
Machácková E; Foretová L; Navrátilová M; Valík D; Claes K; Messiaen L
Cas Lek Cesk; 2000 Oct; 139(20):635-7. PubMed ID: 11192759
[TBL] [Abstract][Full Text] [Related]
20. Functional variant of KLOTHO: a breast cancer risk modifier among BRCA1 mutation carriers of Ashkenazi origin.
Wolf I; Laitman Y; Rubinek T; Abramovitz L; Novikov I; Beeri R; Kuro-O M; Koeffler HP; Catane R; Freedman LS; Levy-Lahad E; Karlan BY; Friedman E; Kaufman B
Oncogene; 2010 Jan; 29(1):26-33. PubMed ID: 19802015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]